CEMPRA, INC. (NASDAQ:CEMP) Files An 8-K Results of Operations and Financial Condition

Item2.02. Results of Operations and Financial Condition.

On February28, 2017, Cempra, Inc. issued a press release
announcing its operating results for the fourth quarter and full
year ended December31, 2016, and provided an update on recent
corporate developments. A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated herein in its entirety
by reference.

The information in this Item2.02 (including Exhibit 99.1) shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits

About CEMPRA, INC. (NASDAQ:CEMP)

Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).

CEMPRA, INC. (NASDAQ:CEMP) Recent Trading Information

CEMPRA, INC. (NASDAQ:CEMP) closed its last trading session up +0.15 at 4.20 with 7,563,993 shares trading hands.